中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
CHINESE JOURNAL OF ANESTHESIOLOGY
2009年
2期
101-104
,共4页
周雅春%张俊杰%汪正平%李士通%王莹恬
週雅春%張俊傑%汪正平%李士通%王瑩恬
주아춘%장준걸%왕정평%리사통%왕형념
尼可地尔%术前用药法%心肺转流术%心肌%冠状动脉分流术
尼可地爾%術前用藥法%心肺轉流術%心肌%冠狀動脈分流術
니가지이%술전용약법%심폐전류술%심기%관상동맥분류술
Nieorandil%Premedication%Cardiopulmonary bypass%Myocardium%Coronary artery bypass
目的 评价尼可地尔术前用药对体外循环(CPB)下冠状动脉旁路移植术(CABG)患者的心肌保护作用.方法 择期CPB下CABG患者30例,年龄45~64岁,体重45~90 kg,ASAⅡ或Ⅲ级.随机分为2组(n=15):对照组(C组)和尼可地尔组(N组).N组麻醉前30 min口服尼可地尔10 mg,C组麻醉前不给予尼可地尔.于手术开始时(T1)、停CPB后即刻(T2)、30 min(T3)、60 min(T4)、术毕(T5)时记录HR、MAP、平均肺动脉压(MPAP)、肺毛细血管楔压(PCWP)、中心静脉压(CVP)和心排血量(CO),计算每搏指数(SI)、左室每搏功指数(LVSWI)、右室每搏功指数(RVSWI)、周围血管阻力(SVR)和肺血管阻力(PVR).于麻醉诱导前(T0,基础状态)、T3、术后6 h(T6)、24 h(T7)时采集静脉血样8ml,采用ELLSA法测定血清心肌肌钙蛋白Ⅰ(cTnⅠ)浓度.结果 与C组比较,N组T7时血清cTnⅠ浓度降低(P<0.05).与基础值比较,C组其余各时点血清cTnⅠ浓度升高(P<0.01),N组其余各时点血清cTnI浓度差异无统计学意义(P>0.05).与C组比较,N组SVR降低(P<0.05),其余血液动力学指标差异无统计学意义(P>0.05).结论 术前30 min口服尼可地尔10 mg对体外循环下冠状动脉旁路移植术患者具有一定程度的心肌保护作用.
目的 評價尼可地爾術前用藥對體外循環(CPB)下冠狀動脈徬路移植術(CABG)患者的心肌保護作用.方法 擇期CPB下CABG患者30例,年齡45~64歲,體重45~90 kg,ASAⅡ或Ⅲ級.隨機分為2組(n=15):對照組(C組)和尼可地爾組(N組).N組痳醉前30 min口服尼可地爾10 mg,C組痳醉前不給予尼可地爾.于手術開始時(T1)、停CPB後即刻(T2)、30 min(T3)、60 min(T4)、術畢(T5)時記錄HR、MAP、平均肺動脈壓(MPAP)、肺毛細血管楔壓(PCWP)、中心靜脈壓(CVP)和心排血量(CO),計算每搏指數(SI)、左室每搏功指數(LVSWI)、右室每搏功指數(RVSWI)、週圍血管阻力(SVR)和肺血管阻力(PVR).于痳醉誘導前(T0,基礎狀態)、T3、術後6 h(T6)、24 h(T7)時採集靜脈血樣8ml,採用ELLSA法測定血清心肌肌鈣蛋白Ⅰ(cTnⅠ)濃度.結果 與C組比較,N組T7時血清cTnⅠ濃度降低(P<0.05).與基礎值比較,C組其餘各時點血清cTnⅠ濃度升高(P<0.01),N組其餘各時點血清cTnI濃度差異無統計學意義(P>0.05).與C組比較,N組SVR降低(P<0.05),其餘血液動力學指標差異無統計學意義(P>0.05).結論 術前30 min口服尼可地爾10 mg對體外循環下冠狀動脈徬路移植術患者具有一定程度的心肌保護作用.
목적 평개니가지이술전용약대체외순배(CPB)하관상동맥방로이식술(CABG)환자적심기보호작용.방법 택기CPB하CABG환자30례,년령45~64세,체중45~90 kg,ASAⅡ혹Ⅲ급.수궤분위2조(n=15):대조조(C조)화니가지이조(N조).N조마취전30 min구복니가지이10 mg,C조마취전불급여니가지이.우수술개시시(T1)、정CPB후즉각(T2)、30 min(T3)、60 min(T4)、술필(T5)시기록HR、MAP、평균폐동맥압(MPAP)、폐모세혈관설압(PCWP)、중심정맥압(CVP)화심배혈량(CO),계산매박지수(SI)、좌실매박공지수(LVSWI)、우실매박공지수(RVSWI)、주위혈관조력(SVR)화폐혈관조력(PVR).우마취유도전(T0,기출상태)、T3、술후6 h(T6)、24 h(T7)시채집정맥혈양8ml,채용ELLSA법측정혈청심기기개단백Ⅰ(cTnⅠ)농도.결과 여C조비교,N조T7시혈청cTnⅠ농도강저(P<0.05).여기출치비교,C조기여각시점혈청cTnⅠ농도승고(P<0.01),N조기여각시점혈청cTnI농도차이무통계학의의(P>0.05).여C조비교,N조SVR강저(P<0.05),기여혈액동역학지표차이무통계학의의(P>0.05).결론 술전30 min구복니가지이10 mg대체외순배하관상동맥방로이식술환자구유일정정도적심기보호작용.
Objective To evaluate the myocardial protective effect of nicorandil premedication in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass (CPB). Methods Thirty ASA Ⅱ or Ⅲ patients aged 45-64 yr weighing 45-90 kg undergoing coronary artery bypass grafting under cardiopulmonary bypass were randomized into 2 groups (n = 15 each): nicorandil group (N) and control group (C). The patients received nieorandil 10 mg orally 30 min before induction of anesthesia in group N, but the patients received no nicorandil before induction of anesthesia in group C. HR, MAP, mean pulmonary arterial pressure (MPAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP) and cardiac output (CO) were recorded and stroke index (SI), left ventricular stroke work index (LVSWI), right ventriculur stroke work index (RVSWI),systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR) were determined at the beginning of operation (T1), immediately after termination of CPB (T2), 30 min (T3) and 60 min (T4) after CPB and at theend of operation(T5). Venous blood samples were taken before the induction of anesthesia (To, baseline), at T3and at 6 h (T6) and 24 h (T7) after operation for determination of serum concentration of cardiac tropin Ⅰ (cTnⅠ)by ELISA. Results Serum cTnⅠ concentration was significantly lower at T7 in group N than in group C (P <0.05). Serum cTnⅠ concentration was significantly increased at the other time points in group C (P<0.01), but there was no significant change in serum cTnⅠ concentration at the other time points in group N as compared with the baseline value(P>0.05). SVR was significantly lower in group N than in group C (P<0.05), but there was no significant difference in the other hemodynamic parameters between the two groups (P>0.05). Conclusion Nieorandil 10 mg premedicated orally 30 min before the operation exerts myocardial protective effect in patients undergoing coronary artery bypass grafting with eardiopulmonary bypass.